<DOC>
	<DOCNO>NCT00930683</DOCNO>
	<brief_summary>To evaluate safety tolerability multiple-dosed drug ( MEDI-546 ) adult scleroderma .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Multiple Doses MEDI-546 Adult Subjects With Scleroderma</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability single multiple IV dose MEDI-546 adult subject scleroderma skin thicken area suitable repeat biopsy .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<criteria>Male female subject ≥ 18 year age time first dose MEDI546 ; Written inform consent HIPAA authorization ( applies cover entity US ) obtain subject subject 's legal representative ; Must fulfill American Rheumatism Association ( American College Rheumatology ) preliminary classification criterion systemic sclerosis ; Has least moderate skin thickening ( score least 2 modify Rodnan Total Skin Score [ mRTSS ] ) least one area suitable repeat biopsy , arm , leg , trunk ; Women , unless surgically sterile ( include tubal ligation ) least 2 year postmenopausal , must use effective method avoid pregnancy ( include oral , injectable , transdermal , implanted contraceptive , intrauterine device , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) addition use condom ( male female condom spermicide ) signing inform consent end study . Cessation birth control point discuss responsible physician . Men , unless surgically sterile , must likewise practice 2 effective method birth control ( condom spermicide abstinence ) must use precaution Study Day 0 end study ; Ability complete study period , include followup period maximum Study Day 105 ; Willing forego form experimental treatment study . History allergy reaction component MEDI546 formulation ; Forced vital capacity ( FVC ) &lt; 60 % predict , diffuse capacity carbon monoxide ( DLCO ) &lt; 40 % predict , pulmonary hypertension require treatment endothelin receptor antagonists prostacyclin analogue , scleroderma renal crisis within last year , medically significant malabsorption ; Have receive following medication within 28 day entry : Cyclophosphamide dose Systemic cyclosporine dose Thalidomide dose Hydroxychloroquine &gt; 600 mg/day Mycophenolate mofetil &gt; 3 g/day Methotrexate &gt; 25 mg/week Azathioprine &gt; 3 mg/kg/day ; Have receive leflunomide &gt; 20 mg/day within 6 month entry ; Have receive fluctuating dos follow within 28 day entry : Antimalarials Mycophenolate mofetil Methotrexate Leflunomide Azathioprine ; Have receive prednisone &gt; 20 mg/day fluctuating dos within 14 day entry ; Have receive fluctuating dos nonsteroidal antiinflammatory drug ( NSAIDs ) within 14 day entry ; Treatment investigational drug therapy within 28 day entry study , B celldepleting therapy within 12 month entry , biologic therapy within 30 day 5 halflives biologic agent , whichever longer , entry study ; In investigator 's opinion , evidence clinically significant active infection , include ongoing , chronic infection , within 28 day entry ; A history severe viral infection judge investigator , include severe infection either cytomegalovirus ( CMV ) herpes family disseminate herpes , herpes encephalitis , ophthalmic herpes ; Herpes zoster infection within 3 month entry ; Evidence infection hepatitis B C virus , human immunodeficiency virus ( HIV ) 1 HIV2 , active infection hepatitis A , determined result test screening ; Vaccination live attenuate virus within 28 day entry ; Pregnancy ( woman , unless surgically sterile least 2 year postmenopausal , must negative serum pregnancy test within 28 day receive MEDI546 negative urine pregnancy test day MEDI546 administration receive MEDI546 ) ; Breastfeeding lactate woman ; History primary immunodeficiency ; History alcohol drug abuse &lt; 1 year prior entry ; History cancer except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior entry ; History active tuberculosis ( TB ) infection latent TB infection without completion appropriate course treatment ; Newly positive TB skin test ( define reaction ≥ 10 mm diameter systemic immunosuppressive medication ≥ 5 mm systemic immunosuppressive medication ) without concomitant prophylactic therapy ; Elective surgery plan time signing inform consent end study ; At screen blood test ( within 28 day entry ) , follow : Aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal range ( ULN ) , unless due Myositis Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Creatinine &gt; 4.0 mg/dL Creatinine &gt; 4.0 mg/dL Neutrophils &lt; 1,500/mm3 Platelet count &lt; 50,000/mm3 ; History disease , evidence current disease ( scleroderma ) , find upon physical examination , chest xray , laboratory abnormality , opinion investigator medical monitor , may compromise safety subject study confound analysis study ; Any employee research site involve conduct study . History vasculitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>